Since the results of the US election, the news has been awash with what the future might hold under a second Trump Administration, particularly within healthcare and life sciences.
In today’s podcast, web editor Nicole Raleigh is joined by Jesse Mendelsohn, senior vice president of Model N’s Center of Excellence, for a conversation that explores multiple aspects of the drug pricing debate in America – speaking before President-Elect Donald Trump confirmed his nomination of Robert F Kennedy Jr as US Health and Human Services Secretary.
Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes to the Inflation Reduction Act, rather than repeal of it. And he explores the potential impacts on pharma, also.
You can listen to episode 158a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts! This article was originally published on PharmaPhorum.
